1st Quarter - Amendment

PFIZER INC. for PFIZER INC.

Firm
Client
Income
—
Expenses
$3,850,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2011 $3,790,000 Replaced
1st Quarter - Amendment (this page) May 18, 2012 $3,850,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership Negotiations US - EU Dialogues (TEC) - market access and regulatory issues Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement Russia market access (no bills) Israel Patent Issues (no bills) APEC Life Sciences Innovation Forum Brazil IP Thailand Compulsory Licensing India IP and Market Access issues Australian FTA Implementation Special 301 Reform Legislation

LobbyistCovered position, as disclosed
JOSEPH DAMOND —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); State, Dept of (DOS); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Repatriation Deferral Deferral for active-financing income- extension S. 1203 - R& D Tax Credit Extension and Enhancement H.R. 422 - R&D Tax Credit Extension and Enhancement H.R. 2098 - CFC Look Through Extension

LobbyistCovered position, as disclosed
MARIA CINO —
KEN W COLE —
ANTHONY PRINCIPI —

Contacted: Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1203 (112th), H.R. 2098 (112th), H.R. 422 (112th)

Copyright/Patent/Trademark CPT

Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S.23 - America Invents Act, 2011 S. 27 - Preserve Access to Affordable Generics H.R. 1249 - America Invents Act, 2011

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
MARY BRIDGET WALSH New Deputy Legislative Director and Counsel
JENNIFER SWENSON WALTON New —

Contacted: Executive Office of the President (EOP); Commerce, Dept of (DOC); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 23 (112th), H.R. 1249 (112th), S. 27 (112th)

Health Issues HCR

Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Medicare Part D Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance H.R. 965 The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979 FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452 Medicare Decision Accountability Act, 2011 S. 668 Health Care Bureacrats Elimination Act, 2011

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
MARY BRIDGET WALSH New Deputy Legislative Director and Counsel
JENNIFER SWENSON WALTON New —

Contacted: Patent & Trademark Office (PTO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Bills named: H.R. 979 (112th), S. 668 (112th), H.R. 452 (112th), H.R. 965 (112th)

Consumer Issues/Safety/Products CSP

Importation The Food, Drug and Cosmetic Globalization Act Dextromethorphan Distribution Dextromethorphan Abuse Reduction H.R. 741 - Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373 - Fair Prescription Drug Competition Act, 2011

LobbyistCovered position, as disclosed
JOHN PAUL HALLIWELL —
JENNIFER SWENSON WALTON New —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); SENATE

Bills named: H.R. 741 (112th), S. 373 (112th)

Medicare/Medicaid MMM

Medicare Prescription Drug Benefit Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation

LobbyistCovered position, as disclosed
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
JENNIFER SWENSON WALTON New —

Contacted: Executive Office of the President (EOP); Commerce, Dept of (DOC); State, Dept of (DOS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.